Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walter Mazzei

Clinical Cardiac Electrophysiology Columbia, SC Medical Doctor

NPI 1083948285 CMS profile 230314

8 Richland Medical Park Dr, Suite 300, Columbia, SC 29203

Open in the dashboard

General payments

$96,397

531 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$157,739 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Walter Mazzei of Columbia, SC is reported in the CMS Open Payments database as having received $96,397 across 531 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $157,739 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $87,618 128
2024 General $1,786 94
2023 General $2,051 86
2022 General $843 39
2021 General $1,478 65
2020 General $1,309 62
2019 General $1,312 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walter Mazzei
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Walter Mazzei were reported at $87,618. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Walter Mazzei Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,312 $2,361 $585–$8,260 $163
2020 $1,309 $993 $247–$4,351 $114
2021 $1,478 $1,185 $326–$4,739 $132
2022 $843 $2,073 $554–$6,789 $149
2023 $2,051 $2,568 $759–$8,159 $160
2024 $1,786 $2,557 $703–$7,403 $164
2025 $87,618 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $87,623 137 payments
  2. Medtronic, Inc. $3,298 149 payments
  3. Medtronic Vascular, Inc. $1,836 85 payments
  4. Biosense Webster, Inc. $1,255 31 payments
  5. Novartis Pharmaceuticals Corporation $430 29 payments
  6. Pfizer Inc. $313 15 payments
  7. Philips Electronics North America Corporation $293 11 payments
  8. E.R. Squibb & Sons, L.L.C. $241 14 payments
  9. Atricure, Inc. $234 10 payments
  10. Cardiva Medical, Inc. $234 17 payments
  11. Other $640 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $85,625 47 payments
  2. Food and Beverage $10,772 484 payments
Products named General payments · program years 2019–2025
  1. General - EP $85,660 51 payments
  2. Micra $1,102 59 payments
  3. Carto 3 $690 18 payments
  4. WATCHMAN Access System $648 30 payments
  5. Reveal LINQ $447 11 payments
  6. Arctic Front $438 4 payments
  7. Carto 3 System $429 6 payments
  8. AZURE XT DR MRI SURESCAN $417 17 payments
  9. Advisa $383 26 payments
  10. LINQ II $366 17 payments
  11. Other $5,813 295 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,675

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$549,515

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

42.6%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 373 $421,479
Xarelto Rivaroxaban Brand 102 $94,960
Dofetilide Generic 55 $9,397
Flecainide Acetate Generic 105 $5,597
Sotalol Sotalol Hcl Brand 114 $3,368
Metoprolol Succinate Generic 162 $3,152
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 55 $2,296
Metoprolol Tartrate Generic 96 $1,223
Warfarin Sodium Generic 65 $1,190
Amiodarone Hcl Generic 70 $903

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$646,041

Medicare's payments for the services billed

Medicare patients

2,297

Average age 76

Services billed

11,532

1,114 women, 1,183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 59%
Ischemic heart disease 56%
Arthritis 52%
Heart failure 45%
Diabetes 39%
Chronic kidney disease 39%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $132
$132 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $38
$38 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $27
$27 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $16
$16 — —
ELIQUIS
  • PFIZER INC. $11
$11 373 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

531 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record